First Opinion - STAT

First Opinion - STAT

I wonder why Dennis Byron needs to call me and others names and to become angry. He can keep insisting that the choice of Part D plans is easy but I have received scores of emails, in addition to the site comments, in which people express their struggles and frustration. Kaiser Family Foundation sent me this: https://www.google.com/amp/s/www.kff.org/medicare/fact-sheet/an-overview-of-the-medicare-part-d-prescription-drug-benefit/amp/ Below is an email I got from a Medicare advisor confirming that many people struggle with the choices and urging further advocacy for change. From: Joseph R Date: 1/1/20 17:22 (GMT-05:00) To: altman1@comcast.net Subject: Medicare Article Michael, My name is Joe R and I enjoyed reading your article and fully understand your frustration with the Medicare system. I’m a SHIP counselor in IL. SHIP is a national organization that provides free, impartial counseling to seniors who need help with Medicare. You’re correct that there are too many choices whether its Medicare D drug plans, Medicare supplement plans or Medicare Advantage plans. Each year seniors are expected to compare their current drug or Advantage plan to the many other plans which can be an overwhelming task especially as they age. Consequently, many seniors forgo plan comparisons and stay with their current plan even though there may be better plans in terms of costs and benefits. It’s unfortunate that Medicare makes it so difficult for seniors and I encourage you to continue to be an advocate for a simpler system. Joe R



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More